Voyager Therapeutics

About:

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Website: https://www.voyagertherapeutics.com/

Twitter/X: VoyagerTx

Top Investors: Fidelity, Deerfield, Wellington Management, Third Rock Ventures, Neurocrine Biosciences

Description:

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Total Funding Amount:

$374M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)voyagertherapeutics.com

Founders:

Guangping Gao, Krystof Bankiewicz, Mark Kay, Phillip D. Zamore

Number of Employees:

101-250

Last Funding Date:

2024-01-04

IPO Status:

Public

© 2025 bioDAO.ai